Search

News How Does Emicizumab Work in Obese Adults with Hemophilia A?

What is the annual bleeding rate and minimum concentration of emicizumab in obese adults with hemophilia A compared to non-obese individuals? Answers were sought by the authors of a pooled post hoc analysis of the HAVEN 1, 3, and 4 studies, the results of which were presented in the poster section of the 2021 ISTH virtual congress. Based on modeling, body weight appears to be an important predictor of emicizumab pharmacokinetics.

Source: Quality Life Even with Hemophilia 1. 12. 2021

News Effects of Telmisartan on Vascular Endothelial Functions, Inflammation Parameters, and Insulin Resistance in Patients with CHD and DM

Patients with coronary heart disease (CHD) and diabetes mellitus (DM) often have dysfunctional vascular endothelium, increased inflammatory markers, and insulin resistance. The study presented below investigated the effects of telmisartan on these parameters associated with disease progression and worse prognosis.

Source: Sartans in the Treatment of Hypertension 2. 3. 2020

News When to Stop Dabigatran Anticoagulation Treatment Before Catheter Ablation in Patients with Atrial Fibrillation?

Catheter ablation is now a standard method of treating atrial fibrillation. Its most common complications are bleeding and thromboembolism. The aim of the analysis of 2 clinical studies presented below, whose conclusions were recently published, was to determine the optimal timing of stopping dabigatran anticoagulation treatment before this procedure.

Source: Anticoagulant Treatment 22. 7. 2021

News Long-term Clinical and Radiological Results of Implantation of Cementless Corail Stem

The Corail femoral stem with extensive hydroxyapatite coating for cementless implantation was introduced to the market several decades ago. The study cited below evaluated the clinical and radiological results of the implantation of this type of stem over a 20-year horizon in patients who underwent primary total hip arthroplasty.

Source: Large Joints 2. 10. 2020

News Antiviral and Anti-inflammatory Effects of Alpha-1-Antitrypsin in the Treatment of COVID-19

Human alpha-1-antitrypsin (AAT) is a circulating blood glycoprotein that has been used for decades in the treatment of patients with AAT deficiency, lung damage, and emphysema, helping to prevent acute lung injury. Recently, it has been found that AAT also mitigates the course of COVID-19 disease by hindering the entry of the SARS-CoV-2 coronavirus into host cells. This dual antiviral and anti-inflammatory action makes AAT an excellent candidate for COVID-19 treatment.

Source: Deficiency of Alpha-1-Antitrypsin 14. 5. 2021

News Effect of Trifluridine/Tipiracil Combination Depending on Patient Prognosis

The results of the RECOURSE clinical study were published in 2015 and became an important basis for the approval of the trifluridine/tipiracil combination in the treatment of metastatic colorectal cancer (mCRC). The data obtained in this study were also subjected to several post-hoc analyses. One of these recently brought information on how patient prognosis affects the clinical outcomes of this treatment.

Source: Treatment of Gastrointestinal Carcinomas 19. 6. 2020

News Do real-world clinical practice data confirm the results of cenobamate treatment in the clinical program?

A recent study by Spanish authors presents the largest dataset of patients with published cenobamate treatment results under prolonged observation in real-world clinical practice at the time of article publication. Data are derived from an expanded access program for a population with highly drug-resistant focal seizures.

Source: Epilepsy 13. 9. 2023

News Safety of aPCC in Real Practice –⁠ Results of the BAHAS Project

What are the experiences with activated prothrombin complex concentrate (aPCC) in controlling bleeding or preventing its recurrence in acquired hemophilia A? The BAHAS project from Spanish real practice offers answers.

Source: Hemophilia 31. 10. 2023

News Thromboprophylaxis in Generalized Pancreatic Cancer

Pancreatic adenocarcinoma is one of the tumors with the highest risk of developing thromboembolic disease (TED). Although anticoagulant treatment reduces the risk of TED, its positive effect on the overall survival of patients has not yet been proven.

Source: Thromboprophylaxis 28. 5. 2021

Články časopisu Study of biocompatibility of peritoneal dialysis solutions measured as in vitro cells viability

Author of the article: Nataliia Hudz, Anna Filipska, Nataliia Stepaniuk, Nataliia Dmytrukha, Raisa Korytniuk, Piotr P. Wieczorek Source: Česká a slovenská farmacie | 4/2019 21. 8. 2019

News Venetostart –⁠ The First Comprehensive Mobile Application with Practical Information for Venetoclax Treatment

Abbvie has developed the comprehensive mobile application Venetostart with practical information needed in clinical practice for administering venetoclax (Venclyxto), which is indicated for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML).

Source: Chronic Lymphocytic Leukemia 27. 2. 2023

News ERS 2023: Erdostein and its Metabolite Met-1 Modulate Innate Immunity and Oxidative Stress in SARS-CoV-2 Infection

As part of the September congress of the European Respiratory Society (ERS 2023), the issue of COVID-19 was also addressed. Among the late-breaking messages was an e-poster by experts from the University of Milan, who in their study examined the potential of erdosteine and its active metabolite Met-1 in treating this disease, based on research into its application to cells infected with SARS-CoV-2.

Source: Cough Therapy 18. 10. 2023

News ITP with Severe Hemorrhagic Manifestations Associated with COVID-19 –⁠ Case Study

There can be numerous causes of newly acquired immune thrombocytopenia (ITP), often being idiopathic. Severe COVID-19 can be associated with ITP manifestations where the standard first-line treatment may not be effective. In life-threatening bleeding situations, adding romiplostim has proven effective, as illustrated by the following case study from authors in Montreal, Canada.

Source: Immune Thrombocytopenia 5. 10. 2022

News Focused on the Effect of Teriflunomide on Lymphocyte Subpopulations

Teriflunomide is a common choice for long-term therapy of the relapsing-remitting form of multiple sclerosis. The use of this immunomodulatory agent results in a decrease in lymphocyte numbers. Its effect on different lymphocyte subpopulations, however, has not been fully elucidated. Italian authors of a study published in the journal Neurology: Neuroimmunology and Neuroinflammation attempted to refine this knowledge.

Source: Multiple Sclerosis 6. 4. 2020

News Turoctocog Alfa Pegol in Surgical Procedures –⁠ Experiences from Pathfinder 3 and 5 Studies

The Haemophilia journal published data in May 2020 from 2 studies that summarize experiences with turoctocog alfa pegol during surgical procedures in adults, adolescents, and children with hemophilia A.

Source: Hemophilia with Movement 7. 4. 2021